Checkpoint Therapeutics, Inc. financial data

Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q1 2025 - 13 May 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 68% % 128%
Debt-to-equity -313% % -119%
Return On Equity 916% % 187%
Return On Assets -431% % 43%

Shares

Label TTM Value / Value Unit Change %
Common Stock, Shares, Outstanding 83,063,733 shares 137%
Entity Public Float $69,336,565 USD 110%
Common Stock, Value, Issued $8,000 USD
Weighted Average Number of Shares Outstanding, Basic 59,823,565 shares 82%
Weighted Average Number of Shares Outstanding, Diluted 59,823,565 shares 82%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $41,000 USD 32%
Research and Development Expense $31,443,000 USD -13%
General and Administrative Expense $24,973,000 USD 182%
Operating Income (Loss) $56,375,000 USD -25%
Nonoperating Income (Expense) $132,000 USD 98%
Net Income (Loss) Attributable to Parent $56,507,000 USD -8%
Earnings Per Share, Basic -1 USD/shares 51%
Earnings Per Share, Diluted -1 USD/shares 51%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $33,042,000 USD 194%
Assets, Current $34,164,000 USD 185%
Assets $34,164,000 USD 185%
Accounts Payable, Current $5,113,000 USD -57%
Employee-related Liabilities, Current $554,000 USD 27%
Liabilities, Current $17,869,000 USD -20%
Liabilities $17,869,000 USD -20%
Retained Earnings (Accumulated Deficit) $381,785,000 USD -17%
Stockholders' Equity Attributable to Parent $16,295,000 USD
Liabilities and Equity $34,164,000 USD 185%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $11,686,000 USD -81%
Net Cash Provided by (Used in) Financing Activities $38,124,000 USD 198%
Common Stock, Shares Authorized 175,000,000 shares 119%
Common Stock, Shares, Issued 83,063,733 shares 137%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $26,438,000 USD 319%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $33,042,000 USD 194%
Deferred Tax Assets, Valuation Allowance $89,403,000 USD 2.5%
Deferred Tax Assets, Gross $89,403,000 USD 2.5%
Deferred Tax Assets, Operating Loss Carryforwards $51,309,000 USD 14%
Additional Paid in Capital $398,072,000 USD 28%